MYMahdi Yadollahzadeh

Mahdi Yadollahzadeh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mahdi Yadollahzadeh has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sleep Apnea Severity in People with Acromegaly: Analysis of Data from Iranian Pituitary Tumor Registry (IPTR)

    by Zeinab Abazari, Mahdi Yadollahzadeh, Manizhe Ataee Kachuee, Nahid Hashemi-Madani, Zahra Emami, Mohammad Ghorbani, Mohammad E. Khamseh

  • Association between DLCO index and the severity of heart failure: a cross-sectional study

    by Shirin Izadi, Saeedeh Esmaili, Sepideh Emami, Shahrokh Izadi, Mohana Eskandari, Mahdi Yadollahzadeh, Maasoumeh Saleh, Armin Khavandegar, Mahmood Bakhtiyari

    The prognostic role of diffusing capacity of the lung for carbon monoxide (DLCO) in heart failure has not been thoroughly investigated. Therefore, this study aimed to evaluate DLCO variation in dif...


  • Open Access

    Evaluation of Sovodak (sofosbuvir/daclatasvir) treatment outcome in COVID-19 patients compared with Kaletra (lopinavir/ritonavir); a randomized clinical trial

    by Mahdi Yadollahzadeh, Mohana Eskandari, Maryam Roham, Farhad Zamani, Azadeh Laali, Saeed Kalantari, Zeynab Yassin, Erfaneh Movahedi, Mohsen Farrokhpour, Mohamad Taghei Zeiaei, et al.

    Introduction: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection and treatment are significant health organizations’ concerns worldwide. Although there is no proven drug license against the virus, a variety of components have under investigation. Objectives: In this regard, the present study was intended to evaluate the consequences of Sovodak (sofosbuvir/ daclatasvir) treatment in COVID-19 patients compared with Kaletra (lopinavir/ritonavir). Patients and Methods: This study was conducted as a randomized trial using 120 COVID19 confirmed cases between August 19th and September 19th, 2020, in which subjects were classified into two treatment groups, 58 (Sovodak group) and 54 (Kaletra group). Related statistical operations calculated significant outcomes such as survival rate and hazard ratio by SPSS version 16. Sovodak was composed of sofosbuvir 400mg and daclatasvir 60mg, and Kaletra included lopinavir 400 mg and ritonavir 100 mg. Results: We observed that there was no significant difference concerning the comorbidities, death, intensive care unit admission, remission. Besides, Kaletra had a higher rate of discharge versus Sovodak [HR=1.551 (95% CI=1.008-2.386), P =0.046] and a better outcome was observed in patients receiving. Conclusion: Sovodak compared to Kaletra by Hazard plot. Sovodak (sofosbuvir/daclatasvir) therapy in COVID19 cases was accompanied by a significantly higher survival rate and better outcome than Kaletra (lopinavir/ritonavir). Trial Registration: This study has been registered in the Iranian Registry of Clinical Trials (identifier: IRCT20200328046885N1; https://en.irct.ir/trial/47565, Ethical code #IR.IUMS.FMD.REC.1399.407).


  • Open Access

    Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit

    by Mohsen Farrokhpour, Nader Rezaie, Najmeh Moradi, Fatemeh Ghaffari Rad, Shirin Izadi, Mehdi Azimi, Farhad Zamani, Shahrokh Izadi, Mitra Ranjbar, Mahin Jamshidi Makiani, et al.

    Background: Severe coronavirus disease 2019 (COVID-19) may lead to the cytokine storm syndrome which may cause acute respiratory failure syndrome and death. Our aim was to investigate the therapeutic effects of infliximab, intravenous gammaglobulin (IVIg) or combination therapy in patients with severe COVID-19 disease admitted to the intensive care unit (ICU). Methods: In this observational research, we studied 104 intubated adult patients with severe COVID-19 infection (based on clinical symptoms, and radiographic or CT scan parameters) who were admitted to the ICU of a multispecialty hospital during March 2020 in Tehran, Iran. All cases received standard treatment regimens as local protocol (Oseltamivir + hydroxychloroquine + lopinavir/ritonavir or sofosbuvir or atazanavir ± ribavirin). The cases were grouped as controls (n = 43), infliximab (n = 27), IVIg (n = 23) and combination (n = 11). Results: There was no significant difference between controls and treatment groups in terms of underlying diseases or the number of underlying diseases. The mean age (SD) of cases was 72.42 (16.06) in the control group, 64.52 (12.965) in IVIg, 63.40 (17.57) in infliximab and 64.00 (11.679) in combination therapy; (P = 0.047, 0.031 and 0.11, respectively). Also, 37% in the infliximab group, 26.1% in IVIg, 45.5% in combination therapy, and 62.8% in the control group expired (all P < 0.05). Hazard ratios were 0.31 in IVIg (95% CI: 0.12-0.76, P = 0.01), 0.30 in infliximab (95% CI: 0.13-0.67, P = 0.004), 0.39 in combination therapy (95% CI: 0.12-1.09, P = 0.071). Conclusion: According to the findings of this study, it seems that infliximab and IVIg, alone or together, in patients with severe COVID-19 disease can be considered an effective treatment.


    • 1 February 2013
      • Vol. 16  (2) , 123-5

    Neuroendocrine tumor of the gallbladder.

    by Fazel Elahi, A. Ahmadzadeh, Mahdi Yadollahzadeh, Kiana Hassanpour, Mohammadreza Babaei

    Neuroendocrine tumors (NET) arise from neuroendocrine cells and are an exceedingly rare malignancy in the gallbladder. In this case report, a 52-year-old woman with complaints of episodic abdominal pain for two months prior was admitted to our hospital. She had no other signs and symptoms and her laboratory tests were within normal limits. Ultrasonography showed a broad-necked mass (26 × 12 mm) in the gallbladder for which she underwent laparoscopic cholecystectomy. The final pathological diagnosis was a high grade neuroendocrine carcinoma of the gallbladder with involvement of the lymph nodes and omentum. The patient received the chemotherapy regimens of gemcitabine plus cisplatin, followed by docetaxel plus sunitinib for her metastatic liver lesions. She also underwent radiofrequency ablation. Serial CT-scans revealed metastatic liver lesions that had decreased in size, with no significant improvement. The patient refused additional treatment and at 46 months, she was doing well with no complaints of any pain, disease recurrence, or metastatic progression.


    • 1 September 2012
      • Vol. 17  (9) , 859-864
    Open Access

    Defining the at risk patients for contrast induced nephropathy after coronary angiography; 24-h urine creatinine versus Cockcroft-Gault equation or serum creatinine level

    by Ahmadreza Assareh, Saeed Yazdankhah, Ahmad Ahmadzadeh, Mahdi Yadollahzadeh, Nasim Nasehi, Habib Haybar

    Background: Definitions of chronic kidney disease (CKD) in many catheterization laboratories have relied on the serum creatinine (Scr) rather than glomerular filtration rate (GFR). Regarding that CKD is the primary predisposing factor for contrast induced nephropathy (CIN), we compared the sensitivity of calculated GFR by 24-h Urine creatinine with Cockcroft-Gault (CG) equation and Scr level to define at risk patients for CIN who were undergone coronary angiography (CAG). Materials and Methods: Two hundred fifty four subjects who were candidate for CAG and had normal creatinine level were enrolled. Before CAG, GFR was calculated from a 24-h urine collection, CG equation and a single Scr sample regarding to previously described protocol. Contrast volume used for each case <100 ml. CIN was defined as a 0.5 mg/dL or 25% elevation in the Scr. Results: CIN occurred in 10.6%. Baseline GFR, the volume of contrast agent, and diabetes were the independent risk factors for CIN. GFR was less than 60 ml/min/1.73 m2 in 28% and 23.2% of patients regarding to 24-h urine creatinine and CG equation, respectively. In CIN prediction, 24-h urine creatinine estimated GFR had 85.2%, 59.3% and CG equation GFR had 78.9%, 81.1% sensitivity and specificity, respectively. Conclusion: Although, GFR estimated by CG equation has less sensitivity than GFR calculated from 24-h creatinine in CIN probability, but it is better than Scr alone and because of cost-effectiveness and convenience using of this method, we suggest at least using CG equation for GFR calculation before CIN, especially in diabetic and/or older than 60 years cases.


    • 1 January 2012
      • Vol. 50  (9) , 603-8

    Clinical, high resolution computed tomography and pulmonary function in sulphur mustard victims.

    by Esmail Idani, Ahmad Ahmadzadeh, Mahdi Yadollahzadeh, Habib Heybar, Armita Valizadeh, Javad Moghimi

    We aimed to evaluate clinical, high resolution computed tomography (HRCT) and pulmonary function test (PFT) findings after 18-23 years of exposure in veterans of sulphur mustard (SM) exposure. We performed a cross-sectional study of 106 patients. Inclusion criteria were 1: documented exposure to SM as confirmed by toxicological analysis of their urine and vesicular fluid after exposure 2: single exposure to SM that cause skin blisters and subsequent transient or permanent sequel. Cigarette smoking and pre-exposure lung diseases were of exclusion criteria. After taking history and thorough respiratory examination, patients underwent high resolution computed tomography and spirometry. Clinical diagnoses were made considering the findings. More than 85% of the patients were complaining of dyspnea and cough. Obstructive pattern (56.6%) was main finding in spirometry followed by restrictive and normal patterns. HRCT revealed air trapping (65.09%) and mosaic parenchymal attenuation patterns (58.49%) as most common results. Established diagnoses mainly were chronic obstructive pulmonary disease (COPD) (54.71%), bronchiolitis obliterans (27.35%) and asthmatic bronchitis (8.49%). There were not any significant association between the clinical findings and results of PFT and HRCT imaging and also between PFT and HRCT findings (P-values were more than 0.05). Considering debilitating and progressive nature of the respiratory complications of SM exposure, attempts are needed for appropriate diagnosis and treatment.


    • 1 November 2011
      • Vol. 14  (6) , 378-80

    Six-year follow up of imatinib therapy for newly diagnosed chronic myeloid leukemia in Iranian patients.

    by Hassan Jalaeikhoo, Ahmad Ahmadzadeh, Gholamreza Toogeh, Habib Heybar, Armita Valizadeh, Ramazan Charoosaei, Mahdi Yadollahzadeh, Manouchehr Keyhani

    The present study reported a six-year follow up of patients with chronic myeloid leukemia who were on imatinib therapy. We performed a retrospective study on a total of 417 patients diagnosed with chronic-phase, Philadelphia-positive (Ph+) chronic myeloid leukemia within six months before study entry. Patients were eligible for the study if they were between 18 and 70 years of age. Enrolled patients were treated at an initial dose of 400 mg of imatinib. The mean age of 417 patients was 40.9±14.5 years; 220 (52%) were men and 197 (47.2%) were women. Complete hematologic response at three months occurred in 99% of patients, 221 (53%) before four weeks and 196 (47%) after four weeks. Adverse events occurred in 17 (4.1%) of patients, relapse in 46 (11%) and death in 31 (7.4%) of our studied population. At 72 months, the estimated rate of overall survival rate was 89%. Our findings showed the efficacy and safety of imatinib mesylate among Iranian patients with chronic myeloid leukemia by hematological and molecular response.


  • Survival of Iranian Patients on Lung Transplant Waiting List: Is There Any Difference?

    by K. Najafizadeh, S. Shafagh, H.R. Khoddami-Vishteh, M. Yadollahzadeh, A. Abbasi-Dezfuli, M.B. Shadmehr, S.S.M. Makki, A. Daneshvar, F. Ghorbani, K. Sheikhy, et al.


  • Open Access

    Sporadic colorectal polyps and mismatch repair proteins

    by Mahdi Yadollahzadeh, Mahsa Molaei, Shohreh Almasi, Sepideh Shivarani, SeyedReza Fatemi, MohammadReza Zali

    Al cancer histopathological changes. Aims: In this study we used immunohistochemistry (IHC) staining in sporadic colorectal polyps to assay functional status of MLH1, MSH2, MSH6, and PMS2 proteins, to track genetic/epigenetic roles of this issue in our patients. Materials and Methods: In this cross-sectional study we assessed all patients who were admitted with sporadic colorectal polyps and underwent polypectomy in endoscopy department during 2004-2008. Result: IHC results were abnormal in 6.8% cases for MLH1, in 4.5% cases for MSH2, in 3% for MSH6, and in 4.8% for PMS2. In all cases with abnormal PMS2, MLH1 was also reported as abnormal. Same results were reported for abnormal MSH2, which is accompanied with abnormal MSH6 in all cases (P values < 0.001). There is no significant difference between IHC staining results, gender, dysplasia grade, adenomatous type, and invasion. On the other hand, there was significant difference between IHC staining results, polyp location, and mean age of patients. The same significant difference was between adenomatous polyps and serrated adenoma polyps by MLH1 and PMS2 (P values < 0.05). Conclusion: According to our findings, maybe MMR dysfunction is the cause of sporadic colorectal polyps in younger age and its increasing risk of dysplasia progression and malignancy progression is only in serrated adenoma. Sporadic polyps in left colon had a higher risk to progress to malignancies, and abnormal IHC staining for MLH1 and PMS2 in serrated polyps is much more than in other adenomatous polyps....